Holen Sie sich die Stockscreener-App
20.30
0.49%
-0.10
Handel nachbörslich:
20.39
0.09
+0.44%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Sarepta Sells Arrowhead Shares To Raise Cash, Pay Arrowhead - insights.citeline.com
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives - Investor's Business Daily
Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; August 25, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - Morningstar
Sarepta Sells Biotech Stake to Raise Cash as Elevidys Troubles Hit Home - Barron's
Sarepta sells Arrowhead shares as partnership, debt payments loom - BioPharma Dive
Sarepta Sells Arrowhead Stake to Fund Milestone Payment - Yahoo Finance
This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week - MSN
Sarepta's Strategic Equity Sale and Its Implications for Biotech Capital Strategies - AInvest
Arrowhead Pharmaceuticals Shares Drop After Sarepta Sells Stake - MSN
Arrowhead Pharmaceuticals stock falls after Sarepta sells shares - Investing.com
Investors in Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your RightsSRPT - PR Newswire
SRPT FRAUD: Sarepta Therapeutics, Inc. Investors are Alerted of the Ongoing Securities Fraud Lawsuit and are Urged to Contact BFA Law by August 25 - Newsfile
Sarepta Sells $174 Million Arrowhead Stock - MarketScreener
Sarepta offloads Arrowhead stake to fund milestone payment - The Pharma Letter
Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Join Class - GlobeNewswire
Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial - Stocktwits
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Hold” by Analysts - Defense World
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics - BioSpace
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Sarepta sells Arrowhead stock, activates $100M milestone payment - MSN
Arrowhead to receive $50 million in stock buyback from Sarepta By Investing.com - Investing.com Nigeria
Arrowhead to receive $50 million in stock buyback from Sarepta - Investing.com
Sarepta sells Arrowhead shares to fund milestone payment for DM1 drug - Investing.com India
Sarepta advances siRNA partnership and sells stake in Arrowhead - MarketScreener
Sarepta Therapeutics Announces Strategic Restructuring Plan - TipRanks
Sarepta sells $174 million in Arrowhead stock, triggers $100 million milestone - StreetInsider
Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment - Sarepta Therapeutics
SAREPTA STOCK: Lose Money on Your Sarepta Therapeutics, - GlobeNewswire
Sarepta Therapeutics, Inc. (SRPT) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 25, 2025 Deadline - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSRPT - FinancialContent
Prasad Returns, Delany Departs, Lilly’s Weight Loss Pill Disappoints and Sarepta’s Fallout Continues - BioSpace
Sarepta Provides New Elevidys Safety Data, Reveals Zero Ambulatory Deaths - BioSpace
2025-08-12 | Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Contact Levi & Korsinsky Before August 25, 2025 to Join Class Action | NDAQ:SRPT | Press Release - Stockhouse
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside - MarketBeat
Sarepta details Elevidys’ liver toxicity data and plans for safety study - Endpoints News
Caught In Sarepta ‘Downdraft,’ Arrowhead Becomes RNAi Knight in Shining Armor - BioSpace
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - FinancialContent
Levi & Korsinsky Urges Sarepta Therapeutics, Inc. (SRPT) Shareholders to Act Before Lead Plaintiff Deadline August 25, 2025 - ACCESS Newswire
Sarepta Therapeutics (SRPT) Declines Again On EMA - GlobeNewswire
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline - ACCESS Newswire
SAREPTA (SRPT) LAWSUIT ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Vinay Prasad returns to role as top vaccine regulator at FDA days after leaving US agency - Reuters
August 25, 2025 Deadline Approaching: Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)Contact Levi & Korsinsky - Newsfile
SRPT COURT REMINDER: Sarepta Therapeutics, Inc. was Sued for Fraud -- Investors are Notified to Contact BFA Law by August 25 Deadline - ACCESS Newswire
Sarepta Therapeutics, Inc. Securities Fraud Class Action - GlobeNewswire
Sarepta stock rises as Jefferies reiterates Buy rating after Elevidys shipments resume - Investing.com Canada
Sarepta stock rating upgraded to Buy by Freedom Broker on ELEVIDYS supply resumption - Investing.com Canada
A mild market reaction for companies on Prasad’s return - BioWorld MedTech
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Benzinga
SRPT LAWSUIT ALERT: The Gross Law Firm Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Unexpected Shifts in the Gene Transfer Technologies Market - openPR.com
SRPT COURT NOTICE: Sarepta Therapeutics Investors may have - GlobeNewswire
Vinay Prasad’s Return to FDA Sends Biotech Shares Tumbling - Bloomberg.com
Vor Bio lures Sarepta exec to be its CCO - The Pharma Letter
SRPT Lawsuit Alert! Class Action Lawsuit Against Sarepta Therapeutics - TipRanks
Biotech sector slips amid reported return of ousted FDA official - MSN
Biotech sector slips amid reported return of ousted FDA official (SRPT:NASDAQ) - Seeking Alpha
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - Defense World
Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light - BioSpace
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) InvestorsLead Plaintiff Deadline on August 25, 2025 - ACCESS Newswire
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):